A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer

NCT07349641 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

55

Enrollment

NIH

Sponsor class

Conditions

Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

Interventions

OTHER: Medical Device Usage and Evaluation
DRUG: Tirzepatide

Sponsor

National Cancer Institute (NCI)